Company Novartis CBOE EUROPE EQUITIES
Equities
0QLR
CH0012005267
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- EUR | - |
|
06-24 | Foreign banks target Switzerland after UBS takeover of Credit Suisse | RE |
06-24 | NOVARTIS AG : Barclays reaffirms its Sell rating | ZD |
Business Summary
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sales per Business
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Established Brands
30.0
%
| - | - | 12,238 | 30.0 % | - |
Oncology
29.9
%
| - | - | 12,213 | 29.9 % | - |
Immunology
17.2
%
| - | - | 7,008 | 17.2 % | - |
Cardiovascular, Renal and Metabolic
14.1
%
| - | - | 5,743 | 14.1 % | - |
Neuroscience
8.9
%
| - | - | 3,633 | 8.9 % | - |
Sales per region
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
39.5
%
| 16,860 | 34.9 % | 16,139 | 39.5 % | -4.28% |
Europe
18.9
%
| 10,469 | 21.7 % | 7,704 | 18.9 % | -26.41% |
Asia/Africa/Australasia
9.1
%
| 4,975 | 10.3 % | 3,700 | 9.1 % | -25.63% |
Germany
7.4
%
| 4,086 | 8.5 % | 3,026 | 7.4 % | -25.94% |
China
7.2
%
| 2,987 | 6.2 % | 2,936 | 7.2 % | -1.73% |
Canada and Latin America
7.0
%
| 3,709 | 7.7 % | 2,854 | 7.0 % | -23.04% |
Japan
4.2
%
| 2,106 | 4.4 % | 1,729 | 4.2 % | -17.90% |
France
3.8
%
| 2,156 | 4.5 % | 1,572 | 3.8 % | -27.09% |
Switzerland
2.9
%
| 926 | 1.9 % | 1,175 | 2.9 % | +26.88% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 31/12/04 | |
Director of Finance/CFO | 59 | 31/12/02 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 15/05/22 |
Steffen Lang
COO | Chief Operating Officer | 57 | 31/03/17 |
Klaus Moosmayer
CMP | Compliance Officer | 56 | 30/11/18 |
Samir Shah
IRO | Public Communications Contact | 63 | 31/12/03 |
Simon Brown
PRN | Corporate Officer/Principal | - | 31/07/13 |
Kees Roks
AUD | Comptroller/Controller/Auditor | 61 | 30/04/22 |
Linda Kanitra
PRN | Corporate Officer/Principal | - | - |
Robert Kowalski
HRO | Human Resources Officer | 56 | 31/08/21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 31/12/12 |
Simon Moroney
BRD | Director/Board Member | 65 | 27/02/20 |
Chairman | 68 | 31/12/12 | |
John Young
BRD | Director/Board Member | 60 | 06/03/23 |
Bridgette Heller
BRD | Director/Board Member | 62 | 27/02/20 |
Ton Büchner
BRD | Director/Board Member | 59 | 31/12/15 |
Charles Sawyers
BRD | Director/Board Member | 65 | 31/12/12 |
Nancy Andrews
BRD | Director/Board Member | 65 | 31/12/14 |
Patrice Bula
BRD | Director/Board Member | 68 | 27/02/19 |
Frans van Houten
BRD | Director/Board Member | 64 | 27/02/17 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 2,189,930,497 | 1,866,336,959 ( 85.22 %) | 233,443,766 ( 10.66 %) | 85.22 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
NOVARTIS AG 6.63% | 145,083,991 | 6.63% | 14,983,623,163 $ |
MORPHOSYS AG 51.00% | 19,235,376 | 51.00% | 1,433,544,095 $ |
SANDOZ GROUP AG 2.99% | 12,886,900 | 2.99% | 457,966,018 $ |
NOVARTIS INDIA LIMITED 70.68% | 17,450,680 | 70.68% | 218,239,949 $ |
THIRD HARMONIC BIO, INC. 6.45% | 2,642,762 | 6.45% | 35,175,162 $ |
ERASCA, INC. 4.74% | 12,307,692 | 4.74% | 31,015,384 $ |
OCULIS HOLDING AG 4.66% | 1,713,521 | 4.66% | 20,151,007 $ |
MOLECULAR PARTNERS AG 4.74% | 1,739,130 | 4.74% | 6,554,381 $ |
413,581 | 5.97% | 5,335,195 $ |
Company contact information
![address Novartis(0QLR)](https://cdn.zonebourse.com/static/address/16414098.png)
Group companies
Name | Category and Sector |
---|---|
Novartis Healthcare Pvt Ltd.
![]() Novartis Healthcare Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Healthcare Pvt Ltd. is an Indian company that manufactures and markets health care and nutritional products. The company is based in Mumbai, India. The company was founded in 1997. The CEO is Sanjay Prabhakar Murdeshwar. |
Pharmaceuticals: Major
|
Novartis Pharma AG
![]() Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. |
Pharmaceuticals: Major
|
Novartis Investment Ltd.
| |
Novartis Holding AG
![]() Novartis Holding AG Financial ConglomeratesFinance Part of Novartis AG, Novartis Holding AG is a Swiss healthcare company that provides solutions to address the evolving needs of patients worldwide. The company is based in Basel, Switzerland. Novartis Holding specializes in Managed Access Programs and is committed to the discovery, development, and marketing of innovative products to improve the well-being of all Canadians. The company prides itself on its commitment to diversity and to nurturing an inclusive and inspiring environment. |
Financial Conglomerates
|
Novartis International AG
![]() Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. |
Pharmaceuticals: Major
|
Novartis Services, Inc.
| |
Novartis Finance SA
|
Finance/Rental/Leasing
|
Novartis BioVenturesAG
![]() Novartis BioVenturesAG Investment ManagersFinance Part of Novartis AG, Novartis BioVenturesAG is an alternative investment manager. The company is based in Basel, Switzerland. |
Investment Managers
|
Novartis Investments SARL
![]() Novartis Investments SARL Financial ConglomeratesFinance Novartis Investments SARL is an investment holding company with interest in medicines and pharmaceuticals sector. The company was founded on July 05, 2002 and is headquartered in Luxembourg. |
Financial Conglomerates
|
Sector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
+55.13% | 815B | |
+45.39% | 654B | |
-6.71% | 354B | |
+21.77% | 337B | |
+10.33% | 302B | |
+17.83% | 247B | |
+2.17% | 229B | |
+9.59% | 171B | |
-3.47% | 159B |
- Stock Market
- Equities
- NOVN Stock
- 0QLR Stock
- Company Novartis